Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials

By sjmartinez • November 28, 2024

Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp KA, Kisa RM, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo MJ, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4688. Epub ahead of print. PMID: 39602111.

Tags: Dermatology, Olive View DoM, Publications

Clarifying Psoriasis Disease Severity: A Position Statement from the National Psoriasis Foundation Medical Board

Blauvelt A, Prussick R, Merola JF, Shahriari M, Cather J, Eakin GS, McCormick Howard L, Lebwohl MG, Armstrong AW, Duffin KC. Clarifying Psoriasis Disease Severity:[...]

Dermatofibrosarcoma Protuberans of the Clavicular Skin in a 70-Year-Old Woman: Case Report and Management

Peng DS, Shen A, Kang Y, Yamamoto RK, Levins P. Dermatofibrosarcoma Protuberans of the Clavicular Skin in a 70-Year-Old Woman: Case Report and Management. Cureus.[...]

Helicobacter pylori as a risk factor for pemphigus and pemphigoid: A US large-scale cohort study using the TriNetX database

Kasperkiewicz M, Ludwig RJ, Curman P. Helicobacter pylori as a risk factor for pemphigus and pemphigoid: A US large-scale cohort study using the TriNetX database.[...]